Genenta Science S.p.A. (GNTA)

IT — Healthcare Sector

Peers: SER TELO CVM INMB MDCX BRNS IPSC MRSN JUNS SKYE

Automate Your Wheel Strategy on GNTA

With Tiblio's Option Bot, you can configure your own wheel strategy including GNTA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol GNTA
Rev/Share 0.0
Book/Share 0.6832
PB 2.7822
Debt/Equity 0.0012
CurrentRatio 6.894
ROIC -0.7665

MktCap 36385775.424
FreeCF/Share -0.3414
PFCF -5.8267
PE -3.9008
Debt/Assets 0.001
DivYield 0
ROE -0.6081

Rating C
Score 2
Recommendation Sell
P/E Score 1
DCF Score 3
P/B Score 2
D/E Score 3

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
No ratings available.

News

Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares

GNTA
Published: October 26, 2025 by: GlobeNewsWire
Sentiment: Neutral

MILAN and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology, today announced that it has entered into a securities purchase agreement with institutional investors to purchase 4,285,715 American Depositary Shares ("ADSs") at an offering price of $3.50 per ADS, for gross proceeds of approximately $15.0 million, before deducting placement agent fees and other estimated offering expenses. All of the securities in the offering were sold by Genenta, and no warrants or other derivative securities were issued in connection with this offering.

image for news Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares

Genenta Science, SpA Announces Participation in the D. Boral Capital Inaugural Global Conference

GNTA
Published: May 08, 2025 by: Newsfile Corp
Sentiment: Neutral

Milan, Italy and New York, New York--(Newsfile Corp. - May 8, 2025) - Genenta Science, SpA (NASDAQ: GNTA), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, at The Plaza Hotel in New York City.

image for news Genenta Science, SpA Announces Participation in the D. Boral Capital Inaugural Global Conference

Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates

GNTA
Published: March 19, 2025 by: GlobeNewsWire
Sentiment: Neutral

MILAN and NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a €20 million ($21.9 million) financing through the issuance of a Mandatory Convertible Bond to ENEA Tech and Biomedical (ETB) to support the expansion of its pipeline by advancing Temferon in metastatic Renal Cell Cancer (mRCC). ETB is a leading private foundation, supervised by the Italian Ministry of Enterprises and Made in Italy, managing over €1,7 billion in assets under management through two funds.

image for news Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates

About Genenta Science S.p.A. (GNTA)

IPO Date 2021-12-15
Website https://www.genenta.com
Industry Biotechnology
CEO Pierluigi Paracchi
Employees 13

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.